ANG Lifesciences Intrinsic Value
ANG Lifesciences intrinsic value. ANG Lifesciences (ANG) median intrinsic value is ₹78.76 from 4 valuation models (range ₹79–₹82), vs current price ₹39.38 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Read ANG dividend track record for the complete payout history and dividend yield track record.
ANG Valuation Methods Summary — DCF, Graham Number & P/E
ANG Lifesciences intrinsic value across 4 models vs current price ₹39.38 — upside/downside and value range per method. Compare with ANG Lifesciences value estimation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹81.54 | ₹73.39 - ₹89.69 | +107.1% | Book Value/Share: ₹40.77, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹78.76 | ₹70.88 - ₹86.64 | +100.0% | Revenue/Share: ₹73.85, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹78.76 | ₹70.88 - ₹86.64 | +100.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹78.56 | ₹62.85 - ₹94.27 | +99.5% | CF Growth: 5.0%, Discount: 15% |
ANG Intrinsic Value vs Market Price — All Valuation Models
ANG Lifesciences fair value range ₹79–₹82 vs current market price ₹39.38 across 4 valuation models. For current market price and key ratios, visit ANG Lifesciences stock price NSE.
ANG Intrinsic Value Analysis — Undervalued or Overvalued?
ANG Lifesciences median intrinsic value ₹78.76, current price ₹39.38 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ANG?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of ANG Lifesciences (ANG) is ₹78.76 (median value). With the current market price of ₹39.38, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹78.56 to ₹81.54, indicating ₹78.56 - ₹81.54.
Is ANG undervalued or overvalued?
Based on our multi-method analysis, ANG Lifesciences (ANG) appears to be trading below calculated value by approximately 100.0%.
ANG Financial Health — Key Ratios vs Industry Benchmarks
ANG Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 21.29 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -7.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.46x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
ANG Cash Flow Quality — Operating & Free Cash Flow
ANG Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹11 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹26 Cr | ₹22 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹25 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |